These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 27918382

  • 1. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial.
    Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-Hady H.
    Pediatr Infect Dis J; 2017 Apr; 36(4):358-363. PubMed ID: 27918382
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
    Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E.
    Crit Care; 2012 Jun 28; 16(3):R113. PubMed ID: 22742765
    [Abstract] [Full Text] [Related]

  • 4. Bacterial sepsis in neonates: Single centre study in a Neonatal intensive care unit in Bosnia and Herzegovina.
    Softić I, Tahirović H, Di Ciommo V, Auriti C.
    Acta Med Acad; 2017 May 28; 46(1):7-15. PubMed ID: 28605923
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Comparison of 3-hour and 30-minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial].
    Wang Z, Shan T, Liu Y, Ding S, Li C, Zhai Q, Chen X, Du B, Li Y, Zhang J, Wang H, Wu D.
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Sep 28; 26(9):644-9. PubMed ID: 25230866
    [Abstract] [Full Text] [Related]

  • 7. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
    Germovsek E, Lutsar I, Kipper K, Karlsson MO, Planche T, Chazallon C, Meyer L, Trafojer UMT, Metsvaht T, Fournier I, Sharland M, Heath P, Standing JF, NeoMero Consortium.
    J Antimicrob Chemother; 2018 Jul 01; 73(7):1908-1916. PubMed ID: 29684147
    [Abstract] [Full Text] [Related]

  • 8. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
    Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML.
    Ann Pharmacother; 2006 Feb 01; 40(2):219-23. PubMed ID: 16449546
    [Abstract] [Full Text] [Related]

  • 9. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
    Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ.
    JAMA; 2018 Feb 27; 319(8):788-799. PubMed ID: 29486041
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
    Zhao HY, Gu J, Lyu J, Liu D, Wang YT, Liu F, Zhu FX, An YZ.
    Chin Med J (Engl); 2017 May 20; 130(10):1139-1145. PubMed ID: 28485312
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N, Ikawa K, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Ohge H, Morikawa N, Sueda T.
    Pancreatology; 2014 May 20; 14(2):95-9. PubMed ID: 24650961
    [Abstract] [Full Text] [Related]

  • 12. Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract.
    Zhou QT, He B, Shen N, Liang Y, Sun LN.
    Drugs Aging; 2017 Feb 20; 34(2):115-121. PubMed ID: 28097633
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I.
    Clin Ther; 2008 May 20; 30(5):868-83. PubMed ID: 18555934
    [Abstract] [Full Text] [Related]

  • 14. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
    Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD.
    Lancet Infect Dis; 2021 Feb 20; 21(2):213-225. PubMed ID: 33058798
    [Abstract] [Full Text] [Related]

  • 15. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ, Cappelletty DM, RECEIPT Study group.
    Pharmacotherapy; 2011 Aug 20; 31(8):767-75. PubMed ID: 21923603
    [Abstract] [Full Text] [Related]

  • 16. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial.
    Lutsar I, Trafojer UM, Heath PT, Metsvaht T, Standing J, Esposito S, de Cabre VM, Oeser C, Aboulker JP, NeoMero Consortium.
    Trials; 2011 Sep 30; 12():215. PubMed ID: 21958494
    [Abstract] [Full Text] [Related]

  • 17. Short versus long infusion of meropenem in very-low-birth-weight neonates.
    Padari H, Metsvaht T, Kõrgvee LT, Germovsek E, Ilmoja ML, Kipper K, Herodes K, Standing JF, Oselin K, Lutsar I.
    Antimicrob Agents Chemother; 2012 Sep 30; 56(9):4760-4. PubMed ID: 22733063
    [Abstract] [Full Text] [Related]

  • 18. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial.
    Lutsar I, Chazallon C, Trafojer U, de Cabre VM, Auriti C, Bertaina C, Calo Carducci FI, Canpolat FE, Esposito S, Fournier I, Hallik M, Heath PT, Ilmoja ML, Iosifidis E, Kuznetsova J, Meyer L, Metsvaht T, Mitsiakos G, Pana ZD, Mosca F, Pugni L, Roilides E, Rossi P, Sarafidis K, Sanchez L, Sharland M, Usonis V, Warris A, Aboulker JP, Giaquinto C, NeoMero Consortium.
    PLoS One; 2020 Sep 30; 15(3):e0229380. PubMed ID: 32130261
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP, Cojutti P, Pea F.
    Clin Pharmacokinet; 2015 Sep 30; 54(9):933-41. PubMed ID: 25850987
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
    Ahmed N, Jen SP, Altshuler D, Papadopoulos J, Pham VP, Dubrovskaya Y.
    J Intensive Care Med; 2020 Aug 30; 35(8):763-771. PubMed ID: 29954243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.